General Surgery Coding Alert - 2005 Issue 6
Oncology: Should You Be Wary Of Proposed Clinical Trial?
Subscribe or sign in to view the full article.
Article Overview
This article reviews a Medicare coverage policy dispute in oncology involving proposed clinical trial coverage for colorectal cancer therapies. It summarizes concerns raised by the Association of Community Cancer Centers and state oncology societies about the draft national coverage decision, the role of the National Cancer Institute-sponsored trials, and broader questions about how CMS approaches coverage for investigational cancer treatments. The piece is relevant to oncology coders, reimbursement staff, compliance teams, and providers following Medicare coverage policy for cancer therapies and clinical research.
Why This Topic Matters
Coverage policy for clinical trials can affect how oncology services are financed and administered. Understanding the debate helps stakeholders track Medicare policy, research participation, and access considerations for cancer therapies.
What You Will Learn
- Why a proposed Medicare coverage policy for oncology clinical trials drew concern
- How cancer organizations framed their objections to the draft coverage approach
- What broad coverage and participation issues were raised around the trials
- How the discussion relates to Medicare coverage processes for innovative cancer therapies
Who Should Read This
- Oncology coders
- Medical billing staff
- Compliance professionals
- Practice administrators
- Oncology providers
- Reimbursement specialists
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com